Natus Medical Inc. (BABY) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Natus Medical Inc. (NASDAQ:BABY) posted its quarterly earnings data on Wednesday. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.34 by $0.05. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%.
Shares of Natus Medical (NASDAQ:BABY) opened at 39.70 on Wednesday. Natus Medical has a 52 week low of $29.54 and a 52 week high of $51.05. The company has a market cap of $1.29 billion, a P/E ratio of 34.22 and a beta of 0.78. The company’s 50-day moving average price is $41.06 and its 200 day moving average price is $37.00.
Several research analysts have recently commented on the company. Benchmark Co. assumed coverage on Natus Medical in a research note on Tuesday, October 4th. They issued a “buy” rating and a $55.00 price objective on the stock. Zacks Investment Research downgraded Natus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, September 28th. Finally, Raymond James Financial Inc. raised Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective on the stock in a research note on Tuesday, September 13th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/natus-medical-inc-baby-releases-quarterly-earnings-results-beats-expectations-by-0-05-eps.html
In other Natus Medical news, insider James B. Hawkins bought 10,000 shares of Natus Medical stock in a transaction that occurred on Wednesday, September 28th. The shares were bought at an average cost of $38.48 per share, with a total value of $384,800.00. Following the transaction, the insider now directly owns 459,725 shares of the company’s stock, valued at approximately $17,690,218. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in BABY. Clinton Group Inc. raised its position in shares of Natus Medical by 0.7% in the second quarter. Clinton Group Inc. now owns 8,614 shares of the company’s stock valued at $326,000 after buying an additional 64 shares in the last quarter. Arizona State Retirement System increased its stake in Natus Medical by 1.8% in the second quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock valued at $650,000 after buying an additional 300 shares during the last quarter. Invictus RG increased its stake in Natus Medical by 8.7% in the second quarter. Invictus RG now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 336 shares during the last quarter. Raymond James & Associates increased its stake in Natus Medical by 2.5% in the second quarter. Raymond James & Associates now owns 14,900 shares of the company’s stock valued at $563,000 after buying an additional 367 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in Natus Medical by 4.7% in the second quarter. Thrivent Financial for Lutherans now owns 16,100 shares of the company’s stock valued at $609,000 after buying an additional 730 shares during the last quarter. 88.00% of the stock is currently owned by institutional investors.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.